Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Market Transgenomic Oncology Diagnostics Outside US

NEW YORK (GenomeWeb News) – Personalized medicine firm Transgenomic today announced that it has signed a deal under which PerkinElmer will market and distribute its portfolio of molecular diagnostic oncology products in all markets outside the US.

PerkinElmer will have non-exclusive rights to sell, market, and distribute, as well as provide field service activities, for the Transgenomic products beginning Jan. 1, 2014, with an initial launch in Europe. Included in the deal is Transgenomics' CRC RAScan kit, which detects genetic mutations helpful in guiding treatment decisions for colorectal cancer, and ACE kits for use on PerkinElmer's LabChip MultiDx platform.

The CRC RAScan kit already has the CE IVD Mark, enabling it to be marketed in Europe and other regions and countries that recognize the CE Mark. Specifically, the test detects the full range of RAS mutations that are relevant to a poor response to EGFR inhibitors.

Financial terms of the arrangement were not disclosed.

Paul Kinnon, president and CEO of Transgenomic, said in a statement that PerkinElmer is "the ideal commercial collaborator for our oncology genetic testing portfolio outside of the US. This portfolio addresses a growing breadth of genetic markers important to assessing risk, prognosis and treatment of a variety of cancers."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.